Summary
The main goals of this study are to learn about the safety of an antibody-drug conjugate called sacituzumab tirumotecan when given with bevacizumab targeted therapy,, including:
- whether people can tolerate it
- whether people who take sacituzumab tirumotecan, with or without bevacizumab, live longer without the cancer getting worse than those who receive standard of care treatment.
You may be eligible for this study is you have platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and have received 4 or more cycles of platinum-based doublet chemotherapy in first-line, and a total of 6 cycles of carboplatin-based doublet chemotherapy in second-line setting for ovarian cancer.
The study has two parts.
Part One
Participants will receive sacituzumab tirumotecan once every 2 weeks plus bevacizumab once every 3 weeks via intravenous (IV) infusion over 6 weeks.
Part Two
Participants will be randomly allocated to one of two treatment groups.
- Experimental Group: sacituzumab tirumotecan every 2 weeks via IV infusion until progressive disease or discontinuation. At the physician's discretion, participants may also receive bevacizumab every 3 weeks via IV infusion.
- Active Comparator Group: local standard of care treatment. At the physician's discretion, participants may also receive bevacizumab every 3 weeks via IV infusion.